Wellington Management Group
XERS icon

Wellington Management Group’s Xeris Biopharma Holdings XERS Stock Holding History

Wellington Management Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7M Buy
2,365,103
+193,749
+9% +$1.24M ﹤0.01% 1089
2026
Q1 		$12.6M Sell
2,171,354
-115,244
-5% -$764K ﹤0.01% 1176
2025
Q4 		$17.9M Buy
2,286,598
+1,705,636
+294% +$13.4M ﹤0.01% 1075
2025
Q3 		$4.73M Buy
580,962
+181,671
+45% +$1.21M ﹤0.01% 1456
2025
Q2 		$1.86M Buy
399,291
+7,192
+2% +$33K ﹤0.01% 1593
2025
Q1 		$2.15M Sell
392,099
-73,013
-16% -$295K ﹤0.01% 1539
2024
Q4 		$1.58M Sell
465,112
-6,532
-1% -$21K ﹤0.01% 1629
2024
Q3 		$1.34M Buy
471,644
+49,535
+12% +$127K ﹤0.01% 1659
2024
Q2 		$950K Buy
422,109
+25,164
+6% +$50.7K ﹤0.01% 1686
2024
Q1 		$877K Buy
+396,945
New +$1.03M ﹤0.01% 1713
2018
Q3 		– Sell
-33,333
Closed -$633K – 2322
2018
Q2 		$633K Buy
+33,333
New +$648K ﹤0.01% 1978

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wellington Management Group's XERS Position: Q2 2026 in Review

Wellington Management Group increased its Xeris Biopharma Holdings (XERS) stake by 8.9% in Q2 2026, buying an estimated $1.24M and bringing the position to 2,365,103 shares worth $18.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1089.

Wellington Management Group first reported a position in XERS in Q2 2018 and has held it in 11 quarters since. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Wellington Management Group held 2,365,103 shares of Xeris Biopharma Holdings worth $18.7M as of Q2 2026.
  • Wellington Management Group bought 193,749 Xeris Biopharma Holdings shares in Q2 2026, an estimated $1.24M.
  • Xeris Biopharma Holdings made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1089 holding.
  • Wellington Management Group first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 11 quarters since.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.